RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) and raises the price target from $23 to $26.
June 27, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Nurix Therapeutics and raises the price target from $23 to $26.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact the stock price of Nurix Therapeutics in the short term. Investors often view such updates as a strong signal of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100